Orthofix Medical Inc (OFIX) reported its second-quarter 2025 earnings, surpassing expectations with an EPS of -0.36 compared to the forecast of -0.41. Revenue reached $203.12 million, exceeding the anticipated $196.16 million. Following the earnings release, Orthofix’s stock surged 15.21% in pre-market trading, reflecting investor optimism.
Key Takeaways
- Orthofix reported better-than-expected EPS and revenue for Q2 2025.
- The stock price increased by 15.21% in pre-market trading.
- Significant growth was noted in US Orthopedics and Bone Growth Therapies segments.
- New product launches and FDA clearances highlight innovation.
- Positive free cash flow and improved gross margins were achieved.
Company Performance
Orthofix demonstrated robust performance in Q2 2025, with a 4% year-over-year increase in net sales to $200.7 million. The company continued to strengthen its position in the spine and fracture markets, benefiting from a 7% increase in US Spine Fixation procedure volume. Orthofix’s strategic focus on product innovation and market penetration has positioned it well against competitors.
Financial Highlights
- Revenue: $203.12 million, a 4% increase YoY.
- Earnings per share: -0.36, beating the forecast by 12.2%.
- Gross margin: 72.7%, up by 140 basis points.
- Adjusted EBITDA: $20.6 million, representing 10.3% of net sales.
- Positive free cash flow of $4.5 million.
Earnings vs. Forecast
Orthofix exceeded earnings expectations with an EPS of -0.36 against a forecast of -0.41, a positive surprise of 12.2%. Revenue also surpassed forecasts, reaching $203.12 million compared to the expected $196.16 million, marking a 3.55% surprise.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.